Michael J. Mauro

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, Hagop M. Kantarjian, Neil P. Shah et al. · New England Journal of Medicine · 2012 · 759 citations · Full text

Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society

Alexander R. Lyon, Susan Dent, Susannah Stanway et al. · European Journal of Heart Failure · 2020 · 717 citations · Full text

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

Jörge E. Cortes, Carlo Gambacorti‐Passerini, Michael W. Deininger et al. · Journal of Clinical Oncology · 2017 · 480 citations · Full text

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis

Jason Gotlib, Hanneke C. Kluin‐Nelemans, Tracy I. George et al. · New England Journal of Medicine · 2016 · 465 citations · Full text

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 449 citations · Full text